Jennifer Richer, PhD

Professor, Pathology

FacultyPhoto

Download CV

Languages
English
Department
Pathology

Professional Titles

  • Professor

Publications

  • Spoelstra, NS, Manning NG, Higashi Y, Darling D, Meenakshi S, Shroyer S, Broaddus RR, Horwitz KB, and JK Richer. The Transcription Factor ZEB1 is Aberrantly Expressed in Aggressive Uterine Cancers. CANCER RESEARCH. In Press, 2006.
  • Carvajal A, Espinoza N, Kato S, Pinto M, Sadarangani A, Monso C, Aranda E, Villalon M, Richer JK, Horwitz KB, Brosens JJ, Owen GI. Related Articles, Links Progesterone Pre-treatment Potentiates EGF Pathway Signaling in The Breast Cancer Cell Line ZR-75*. Breast Cancer Res Treat. 2005 Nov;94(2):171-83.
  • Harvell DM, Richer JK, Allred DC, Sartorius CA, Horwitz KB. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology. 2006 Feb;147(2):700-13. .
  • Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol. 2005 Dec;97(4):328-41
  • Howe, E. N. Dawn R. Cochrane and J.K. Richer. Targets of miR-200c mediate suppression of cell motility and anoikis. BREAST CANCER RESEARCH. 2011 Apr 18;13(2):R45. PMID: 21501518. *Highlighted by DC Radisky BREAST CANCER RESEARCH Jun 10;13(3):110
  • Cochrane, D. R. B. M. Jacobsen, E.N. Howe, D. L. Bain and J. K. Richer. Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer. MOL CELL ENDO. Jan 18 2012 Jan 18 epub ahead of print. PMID: 22330642
  • Cochrane, D.R, Spoelstra NS, Richer JK. The role of miRNAs in progesterone action. MOL CELL ENDO. 2011. 121(10) 361-6. PMID: 21946298
  • Howe EN, Cochrane DR and Richer JK. The miR-200 and miR-221/222 miRNA Families: Opposing Effects on Epithelial Identity. J of MAMMARY GLAND BIOLOGY AND NEOPLASIA. 2012 Feb 17 epub ahead of print PMID: 22330642
  • D'Amato NC, Howe EN, Richer JK. MicroRNA regulation of epithelial plasticity in cancer. Cancer Lett. 2013 Nov 28;341(1):46-55. PubMed PMID: 23228634
  • Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, Richer JK, Anderson SM, Thor AD. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle. 2013 Dec 15;12(24):3759-69. PubMed PMID: 24107633
  • Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the Androgen Receptor in Breast Cancer and Preclinical Analysis of Enzalutamide. Breast Cancer Res. 2014 Jan 22;16(1):R7. [Epub ahead of print] PubMed PMID: 24451109
  • Howe EN, Cochrane DR, Cittelly DM and Richer JK. miR-200c targets a TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer. PLOS One 2012;7(11). PMID: 23185507
  • Cittelly DM, Finlay-Schultz J, Howe E, Spoelstra N, Axlund S, Hendricks P, Jacobsen B, Sartorius CA, JK Richer. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. ONCOGENE. 2012 Jul 2. PMID: 22751119
  • Cittelly, D.M. Irina Dimitrova, Erin N. Howe, Dawn R. Cochrane, Annie Jean, Nicole Spoelstra, Xian Liu, Russell R. Broaddus, Monique A. Spillman, and Richer, JK. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. MOL CANCER THER. 2012 Nov 30. PMID: 23074172.
  • Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2014 Sep 22;0. [Epub ahead of print] PubMed PMID: 25241899
  • Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer. 2014 Dec;5(6):374-89. PubMed PMID: 25213330
  • Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med. 2014 Mar 26;6(229):229ra41. PubMed PMID: 24670685
  • Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014 Jan 22;16(1):R7. PubMed PMID: 24451109
  • Cochrane, D. R. B. M. Jacobsen, E.N. Howe, D. L. Bain and J. K. Richer. Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer. MOL CELL ENDO. 2012 May 15 355 (1): 15-24. PMID: 22330642
  • D’Amato NC, Howe EN, Richer, JK. MicroRNA regulation of epithelial plasticity in cancer. In press CANCER LETTERS 2012 Dec 8. PMID PMID:23228634
  • D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC, Richer JK. A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer. Cancer Res. 2015 Nov 1;75(21):4651-64. PubMed PMID: 26363006
  • Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR or Quadruple Negative Disease. Horm Cancer. 2015 Dec;6(5-6):206-13. PubMed PMID: 26201402
  • Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015 Mar;14(3):769-78. PubMed PMID: 25713333
  • Niemeyer BF, Parrish JK, Spoelstra NS, Joyal T, Richer JK, Jedlicka P. Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes. PLoS One. 2015;10(1):e0116895. PubMed PMID: 25603314
  • Howe EN, Cochrane DR and Richer JK. The miR-200 and miR-221/222 miRNA Families: Opposing Effects on Epithelial Identity. J of MAMMARY GLAND BIOLOGY AND NEOPLASIA. 2012 Feb 17. PMID: 22330642.
  • Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015 Jul;34(28):3676-87. PubMed PMID: 25241899
  • Heinz RE, Rudolph MC, Ramanathan P, Spoelstra NS, Butterfield KT, Webb PG, Babbs BL, Gao H, Chen S, Gordon MA, Anderson SM, Neville MC, Gu H, Richer JK. Constitutive expression of microRNA-150 in mammary epithelium suppresses secretory activation and impairs de novo lipogenesis. Development. 2016 Nov 15;143(22):4236-4248. PubMed PMID: 27729410
  • D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. Cooperative Dynamics of AR and ER Activity in Breast Cancer. Mol Cancer Res. 2016 Nov;14(11):1054-1067. PubMed PMID: 27565181
  • Barton VN, Gordon MA, Richer JK, Elias A. Anti-androgen therapy in triple-negative breast cancer. Ther Adv Med Oncol. 2016 Jul;8(4):305-8. PubMed PMID: 27482289
  • Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK. Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison. Hum Pathol. 2016 Oct;56:40-51. PubMed PMID: 27260947
  • He L, Du Z, Xiong X, Ma H, Zhu Z, Gao H, Cao J, Li T, Li H, Yang K, Chen G, Richer JK, Gu H. Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer. Sci Rep. 2017 Nov 6;7(1):14584. PubMed PMID: 29109513
  • Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, MacLean PS, Anderson SM. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Horm Cancer. 2017 Dec;8(5-6):269-285. PubMed PMID: 28741260
  • Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D'Amato NC, Elias A, Richer JK. Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. Cancer Res. 2017 Jul 1;77(13):3455-3466. PubMed PMID: 28512248
  • Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. Mol Cancer Ther. 2017 Jul;16(7):1389-1400. PubMed PMID: 28468774
  • Christenson JL, Butterfield KT, Spoelstra NS, Norris JD, Josan JS, Pollock JA, McDonnell DP, Katzenellenbogen BS, Katzenellenbogen JA, Richer JK. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. Horm Cancer. 2017 Apr;8(2):69-77. PubMed PMID: 28194662
  • Greene LI, Bruno TC, Christenson JL, Borges VF, Slansky JE, and JK Richer. A role for tryptophan 2,3-dioxygenase in CD8 T cell suppression and evidence of tryptophan catabolism in breast cancer patient plasma. MOLECULAR CANCER RESEARCH. 2018. PMID: 30143553
  • Rogers TJ, Christenson JL, Greene LI, O’Neill K, Williams MM, Gordon MA, Nemkov T, D’Alessandro A, Degala G, Shin J, Tan AC, Cittelly DM, Lambert JR and JK Richer. Reversal of Triple-negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immune-Suppression. Sep 13. doi: 10.1158/1541-7786. MOLECULAR CANCER RESEARCH. 2018. PMID: 30213797
  • Gordon MA, Babbs B, Cochrane DR, Bitler BG, JK Richer. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinog. 2018 Oct 8. PMID: 30294913
  • Christenson JL, Trepel JB, Ali HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. HORMONES AND CANCER. 2018 Apr PMID: 29340907
  • MacFawn I, Wilson H, Selth LA, Leighton I, Serebriiskii I, Bleackley RC, Elzamzamy O, Farris J, Pifer PM, Richer J, Frisch SM. Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers. MOL IMMUN 2018 Nov 30;105:137-149. PMID: 30508726
  • Smith LP, Bitler BG, Richer JK, Christenson JL. Tryptophan catabolism in epithelial ovarian carcinoma. Trends Cancer Res. 2019;14:1-9. PubMed PMID: 31736606
  • Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Sawyer BT, Sullivan KD, Khanal S, Joshi M, Ferchaud-Roucher V, Smith H, Vanderlinden LA, Brubaker SW, Caino CM, Kim H, Espinosa JM, Richer JK, Bitler BG. Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination. iScience. 2019 Sep 27;19:474-491. PubMed PMID: 31437751
  • Gordon MA, Babbs B, Cochrane DR, Bitler BG, Richer JK. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinog. 2019 Feb;58(2):196-205. PubMed PMID: 30294913
  • Rogers TJ, Christenson JL, Greene LI, O'Neill KI, Williams MM, Gordon MA, Nemkov T, D'Alessandro A, Degala GD, Shin J, Tan AC, Cittelly DM, Lambert JR, Richer JK. Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression. Mol Cancer Res. 2019 Jan;17(1):30-41. PubMed PMID: 30213797
  • Greene LI, Bruno TC, Christenson JL, D'Alessandro A, Culp-Hill R, Torkko K, Borges VF, Slansky JE, Richer JK. A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma. Mol Cancer Res. 2019 Jan;17(1):131-139. PubMed PMID: 30143553
  • Rosas E, Roberts JT, O'Neill K, Christenson JL, Williams MM, Hanamura T, Spoelstra NS, Vahrenkamp JM, Gertz J, Richer JK. A Positive Feedback Loop Between TGFß and Androgen Receptor Supports Triple-Negative Breast Cancer Anoikis Resistance. Endocrinology. 2020 Dec 8. [Epub ahead of print] PubMed PMID: 33294922
  • Arnesen S, Blanchard Z, Williams MM, Berrett KC, Li Z, Oesterreich S, Richer JK, Gertz J. Estrogen receptor alpha mutations in breast cancer cells cause gene expression changes through constant activity and secondary effects. Cancer Res. 2020 Nov 12. [Epub ahead of print] PubMed PMID: 33184109
  • Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, Elias A, Gertz J, Richer JK. Steroid hormone receptor and infiltrating immune cell status reveals therapeutic vulnerabilities of ESR1 mutant breast cancer. Cancer Res. 2020 Nov 12. [Epub ahead of print] PubMed PMID: 33184106
  • Crump LS, Wyatt G, Rutherford TR, Richer JK, Porter WW, Lyons TR. Hormonal regulation of Semaphorin 7a in ER breast cancer drives therapeutic resistance. Cancer Res. 2020 Oct 29. [Epub ahead of print] PubMed PMID: 33122307
  • Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020 Dec 1;26(23):6362-6373. PubMed PMID: 32928797
  • Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression. Mol Cancer Res. 2020 Jul;18(7):1088-1098. PubMed PMID: 32198139
  • Smith LP, Bitler BG, Richer JK, Christenson JL. Tryptophan catabolism in epithelial ovarian carcinoma. Trends Cancer Res. 2019;14:1-9. PubMed PMID: 31736606
  • Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Sawyer BT, Sullivan KD, Khanal S, Joshi M, Ferchaud-Roucher V, Smith H, Vanderlinden LA, Brubaker SW, Caino CM, Kim H, Espinosa JM, Richer JK, Bitler BG. Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination. iScience. 2019 Sep 27;19:474-491. PubMed PMID: 31437751
  • Gordon MA, Babbs B, Cochrane DR, Bitler BG, Richer JK. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinog. 2019 Feb;58(2):196-205. PubMed PMID: 30294913
  • Rogers TJ, Christenson JL, Greene LI, O'Neill KI, Williams MM, Gordon MA, Nemkov T, D'Alessandro A, Degala GD, Shin J, Tan AC, Cittelly DM, Lambert JR, Richer JK. Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression. Mol Cancer Res. 2019 Jan;17(1):30-41. PubMed PMID: 30213797
  • Greene LI, Bruno TC, Christenson JL, D'Alessandro A, Culp-Hill R, Torkko K, Borges VF, Slansky JE, Richer JK. A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma. Mol Cancer Res. 2019 Jan;17(1):131-139. PubMed PMID: 30143553
  • Williams MM, Hafeez SA, Christenson JL, O'Neill KI, Hammond NG, Richer JK. Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways. Pharmaceuticals (Basel). 2021 Nov 2;14(11). PubMed PMID: 34832904
  • Hanamura T, Christenson JL, O'Neill KI, Rosas E, Spoelstra NS, Williams MM, Richer JK. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models. Breast Cancer Res. 2021 Nov 4;23(1):102. PubMed PMID: 34736512
  • Bergholtz H, Carter JM, Cesano A, Cheang MCU, Church SE, Divakar P, Fuhrman CA, Goel S, Gong J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, Mittendorf EA, Perez J, Prat A, Pusztai L, Reeves JW, Riazalhosseini Y, Richer JK, Sahin Ö, Sato H, Schlam I, Sørlie T, Stover DG, Swain SM, Swarbrick A, Thompson EA, Tolaney SM, Warren SE, On Behalf Of The GeoMx Breast Cancer Consortium. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx(®) Digital Spatial Profiler. Cancers (Basel). 2021 Sep 4;13(17). PubMed PMID: 34503266
  • Williams MM, Christenson JL, O'Neill KI, Hafeez SA, Ihle CL, Spoelstra NS, Slansky JE, Richer JK. MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer. NPJ Breast Cancer. 2021 May 27;7(1):64. PubMed PMID: 34045467
  • Christenson JL, O'Neill KI, Williams MM, Spoelstra NS, Jones KL, Trahan GD, Reese J, Van Patten ET, Elias A, Eisner JR, Richer JK. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer. Mol Cancer Ther. 2021 Jun;20(6):1062-1071. PubMed PMID: 33722849
  • Porman AM, Roberts JT, Duncan ED, Chrupcala ML, Levine AA, Kennedy MA, Williams MM, Richer JK, Johnson AM. A single N6-methyladenosine site regulates lncRNA HOTAIR function in breast cancer cells. PLoS Biol. 2022 Nov;20(11):e3001885. PubMed PMID: 36441764
  • Rosas E, Roberts JT, O'Neill KI, Christenson JL, Williams MM, Hanamura T, Spoelstra NS, Vahrenkamp JM, Gertz J, Richer JK. A Positive Feedback Loop Between TGFß and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance. Endocrinology. 2021 Feb 1;162(2). PubMed PMID: 33294922
  • Christenson JL, Williams MM, Richer JK. The underappreciated role of resident epithelial cell populations in metastatic progression: contributions of the lung alveolar epithelium. Am J Physiol Cell Physiol. 2022 Dec 1;323(6):C1777-C1790. PubMed PMID: 36252127
  • Crump LS, Kines KT, Richer JK, Lyons TR. Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis. Am J Physiol Cell Physiol. 2022 Nov 1;323(5):C1475-C1495. PubMed PMID: 36189970
  • Camp FA, Brunetti TM, Williams MM, Christenson JL, Sreekanth V, Costello JC, Hay ZLZ, Kedl RM, Richer JK, Slansky JE. Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8( ) T Cell Immunity. Cancers (Basel). 2022 Sep 9;14(18). PubMed PMID: 36139558
  • Arnesen S, Blanchard Z, Williams MM, Berrett KC, Li Z, Oesterreich S, Richer JK, Gertz J. Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects. Cancer Res. 2021 Feb 1;81(3):539-551. PubMed PMID: 33184109
  • O'Neill KI, Kuo LW, Williams MM, Lind H, Crump LS, Hammond NG, Spoelstra NS, Caino MC, Richer JK. NPC1 Confers Metabolic Flexibility in Triple Negative Breast Cancer. Cancers (Basel). 2022 Jul 21;14(14). PubMed PMID: 35884604
  • Williams MM, Richer JK. Revealing Molecular Mechanisms Supporting Trophoblast-Mediated Maternal Immune Tolerance. Endocrinology. 2022 Aug 1;163(8). PubMed PMID: 35797586
  • Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, Elias A, Gertz J, Richer JK. Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1 -Mutant Breast Cancer. Cancer Res. 2021 Feb 1;81(3):732-746. PubMed PMID: 33184106
  • Li Z, Spoelstra NS, Sikora MJ, Sams SB, Elias A, Richer JK, Lee AV, Oesterreich S. Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. NPJ Breast Cancer. 2022 May 10;8(1):62. PubMed PMID: 35538119
  • Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Bruno TC, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nat Commun. 2022 Apr 19;13(1):2011. PubMed PMID: 35440136
  • Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, El-Ashry D, Zhang Q, Gerratana L, Zhang Y, Cristofanilli M, Montanez MA, Sundd P, Wallace CT, Watkins SC, Fumagalli C, Guerini-Rocco E, Zhu L, Tseng GC, Wagle N, Carroll JS, Jank P, Denkert C, Karsten MM, Blohmer JU, Park BH, Lucas PC, Atkinson JM, Lee AV, Oesterreich S. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Res. 2022 Apr 1;82(7):1321-1339. PubMed PMID: 35078818
  • Crump LS, Wyatt GL, Rutherford TR, Richer JK, Porter WW, Lyons TR. Hormonal Regulation of Semaphorin 7a in ER( ) Breast Cancer Drives Therapeutic Resistance. Cancer Res. 2021 Jan 1;81(1):187-198. PubMed PMID: 33122307
  • Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020 Dec 1;26(23):6362-6373. PubMed PMID: 32928797
  • Adler FR, Anderson ARA, Bhushan A, Bogdan P, Bravo-Cordero JJ, Brock A, Chen Y, Cukierman E, DelGiorno KE, Denis GV, Ferrall-Fairbanks MC, Gartner ZJ, Germain RN, Gordon DM, Hunter G, Jolly MK, Karacosta LG, Mythreye K, Katira P, Kulkarni RP, Kutys ML, Lander AD, Laughney AM, Levine H, Lou E, Lowenstein PR, Masters KS, Pe'er D, Peyton SR, Platt MO, Purvis JE, Quon G, Richer JK, Riddle NC, Rodriguez A, Snyder JC, Lee Szeto G, Tomlin CJ, Yanai I, Zervantonakis IK, Dueck H. Modeling collective cell behavior in cancer: Perspectives from an interdisciplinary conversation. Cell Syst. 2023 Apr 19;14(4):252-257. PubMed PMID: 37080161
  • Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression. Mol Cancer Res. 2020 Jul;18(7):1088-1098. PubMed PMID: 32198139
  • Fernández NB, Sosa SM, Roberts JT, Recouvreux MS, Rocha-Viegas L, Christenson JL, Spoelstra NS, Couto FL, Raimondi AR, Richer JK, Rubinstein N. RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer. Cells. 2023 Jan 29;12(3). PubMed PMID: 36766786
  • Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER /HER2- advanced breast cancer. NPJ Breast Cancer. 2023 May 20;9(1):41. PubMed PMID: 37210417
  • Welter L, Zheng S, Setayesh SM, Morikado M, Agrawal A, Nevarez R, Naghdloo A, Pore M, Higa N, Kolatkar A, Thiele JA, Sharma P, Moore HCF, Richer JK, Elias A, Pienta KJ, Zurita AJ, Gross ME, Shishido SN, Hicks J, Velasco CR, Kuhn P. Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. Cancers (Basel). 2023 Aug 3;15(15). PubMed PMID: 37568766
  • Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee A, Walker JK, Steinauer N, Zhang J, Coons LA, Korach KS, Cain DW, Hollenberg AN, Webb P, Forrest D, Jetten AM, Edwards DP, Grimm SL, Hartig S, Lange CA, Richer JK, Sartorius CA, Tetel M, Billon C, Elgendy B, Hegazy L, Griffett K, Peinetti N, Burnstein KL, Hughes TS, Sitaula S, Stayrook KR, Culver A, Murray MH, Finck BN, Cidlowski JA. International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023. Pharmacol Rev. 2023 Nov;75(6):1233-1318. PubMed PMID: 37586884

Personal Interests
I like to read, bike and hike and spend time with my family and friends.

Volunteer Activities
I am on the American Cancer Society Denver Board of Directors

Public Speaking
Yes
Breast cancer


School of Medicine

CU Anschutz
Fitzsimons Building

13001 East 17th Place

Aurora, CO 80045

303.724.5375

School
General
Students